Nirsevimab to reduce infant morbidity from respiratory syncytial virus

CMAJ. 2024 Sep 30;196(32):E1114-E1117. doi: 10.1503/cmaj.240780.

¹ Canadian Center for Vaccinology (Abu-Raya, Langley), Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority; Departments of Pediatrics (Abu-Raya, Langley), of Microbiology and Immunology (Abu-Raya), and of Community Health and Epidemiology (Langley), Dalhousie University, Halifax, NS; Department of Pediatrics (Lavoie), University of British Columbia, Vancouver, BC. Bahaa.AbuRaya@dal.ca.
² Canadian Center for Vaccinology (Abu-Raya, Langley), Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority; Departments of Pediatrics (Abu-Raya, Langley), of Microbiology and Immunology (Abu-Raya), and of Community Health and Epidemiology (Langley), Dalhousie University, Halifax, NS; Department of Pediatrics (Lavoie), University of British Columbia, Vancouver, BC.

No abstract available

Publication types